Malaria Vaccines Market Growing Trade Among Emerging Economies Opening New Opportunities Appraised By Global Players GlaxoSmithKline plc, Sanaria Inc., Nobelpharma Co., Ltd., Sumaya Biotech and GenVec Inc.

Malaria is a severe and widespread disease caused by a parasitic infection by protozoan Plasmodium when transmitted by various species of anopheles mosquitoes. In 2009, according to WHO, 214 Mn to 397 Mn clinical malaria cases were reported worldwide. However, high estimates of around 515 Mn clinical cases of P. falciparum were projected in 2002. Furthermore, malaria accounted for around 3% of the world’s total Disability Adjusted Life Years (DALYs) lost and around 10% in Africa alone. According to Centers for Disease Control and Prevention (CDC), there are around 156 types of Plasmodium species that infect various species of vertebrates. Among the numerous plasmodium species, four are considered true parasites of humans, as they utilize humans almost exclusively as a natural intermediate host: P. falciparum, P. vivax, P. ovale and P. malariae. Over 85% of malaria mortality is due to P. falciparum. Around 90% of deaths caused by malaria in Sub-Saharan Africa is primarily due to P. Falciparum.

Get Exclusive Sample Report at: https://bit.ly/2Urj7qV

Market Dynamics

The growing incidence of malaria globally and major players pledging for low profit margin over vaccines is expected to boost growth of the market for malaria vaccines market. According to World Health Organization (WHO), in 2015, approximately 292,000 children in Africa died of malaria, at very early age of 5 years. Around 306,000 fatalities associated with malaria were reported worldwide in 2015, out of which around 90% cases were reported in Africa. According to World Health Organization (WHO), first global malaria vaccines will be piloted in the regions of sub-Saharan Africa in 2018, with the funding to around US$ 15 Mn. The program is partly funded by the Bill & Melinda Gates Foundation and African Research Centers.

Major regions affected by malaria do not have an appropriate healthcare infrastructure and standard economic conditions, due to which they are unable to pay for the better treatments and drugs. Malaria is common in sub-Saharan and African region, due to poor sanitation and healthcare standards. However, the vaccine is being developed by GSK at their lab in Belgium in collaboration with Path, which is an international non-profit organization. This ensures the cost effectiveness of the vaccine though it has taken around 30 years to develop at a cost of US$ 565 Mn. The company pledges not to make a profit from sales of the vaccine and adheres to the price range of around US$ 5 per shot.

Market Taxonomy

This report segments the global malaria vaccines market on the basis of vaccines type, by agent, distribution channel, and geography. On the basis of vaccines type, the malaria vaccines market is categorized into Pre-Erythrocytic Vaccine, Erythrocytic Vaccine and Multi-antigen Vaccine. On the basis of agent, the malaria vaccines market is categorized into Plasmodium Falciparum and Plasmodium Vivax. On the basis of distribution channel, the malaria vaccines market is categorized into hospital, clinics, and community centers. For comprehensive understanding of market dynamics, the global malaria vaccines market is analyzed across key geographical regions namely North America, Europe, Asia Pacific, Latin America, Africa, and Middle East. Each of these regions is analyzed on basis of market findings across major countries in these regions for a macro-level understanding of the market.

Browse Research Report At: https://bit.ly/2D2ECET

Increasing Accessibility And Government Support To Contribute Towards The Malaria Vaccines Market Growth

The WHO has established a Global Technical Strategy for Malaria 2016-2030 (GTS) in 2015 with certain defined goals, one of them aimed at eliminating malaria in at least 10 countries. Similarly, the Indian government has established Drug Distribution Centers (DDCs) and Fever Treatment Depots (FTDs) in the rural areas for providing easy access to anti-malarial drugs. Regular monitoring and surveillance by various government programs has helped to reduce malarial cases in India from 2.03 million in 2010 to 1.1 million in 2015. Support from such national and global initiatives will drive malaria vaccines market growth during the forecast period.

Many such non-profit organizations and pharmaceutical companies are conducting research on malaria vaccines. Approximately 31 trials are under progress for malaria vaccine development with a few being blood stage projects. Availability of funds and government support programs will encourage commercialization of product with successful trial results, thus boosting the malaria vaccines market growth trajectory.

The P. falciparum vaccines market is projected to be the growth driver with major vaccine candidates targeting this parasite. Revenues through community centers is projected to be high as demand for preventive treatment methods is high from this end-user segment.

Global Key Players:

Key companies covered as a part of this study include GlaxoSmithKline plc, Sanaria Inc., Nobelpharma Co., Ltd., Sumaya Biotech and GenVec Inc.

Request For Customization of Research Report @ https://bit.ly/2I6hjNs

About Coherent Market Insights

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us

Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

This release was published on openPR.